Literature DB >> 22396971

Treatment of neovascular glaucoma after proton therapy for uveal melanomas with ranibizumab injection: preliminary results.

Jean Pierre Caujolle1, Celia Maschi, Aurelien Freton, Gilles Pages, Pierre Gastaud.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22396971     DOI: 10.1159/000328633

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


× No keyword cloud information.
  6 in total

Review 1.  Anti-vascular endothelial growth factor for neovascular glaucoma.

Authors:  Arathi Simha; Andrew Braganza; Lekha Abraham; Prasanna Samuel; Kristina Lindsley
Journal:  Cochrane Database Syst Rev       Date:  2013-10-02

2.  Ranibizumab for the Prevention of Radiation Complications in Patients Treated With Proton Beam Irradiation for Choroidal Melanoma.

Authors:  Ivana K Kim; Anne Marie Lane; Purva Jain; Caroline Awh; Evangelos S Gragoudas
Journal:  Trans Am Ophthalmol Soc       Date:  2016-08

Review 3.  Secondary glaucoma as initial manifestation of ring melanoma: a case report and review of literature.

Authors:  Manli Zhao; Yalin Mu; Yalong Dang; Yu Zhu
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

4.  Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy.

Authors:  Amir Mahdjoubi; Marie Najean; Stéphanie Lemaitre; Sylvain Dureau; Rémi Dendale; Christine Levy; Livia Lumbroso-Le Rouic; Laurence Desjardins; Nathalie Cassoux
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-11-07       Impact factor: 3.117

Review 5.  Anti-vascular endothelial growth factor for neovascular glaucoma.

Authors:  Arathi Simha; Kanza Aziz; Andrew Braganza; Lekha Abraham; Prasanna Samuel; Kristina B Lindsley
Journal:  Cochrane Database Syst Rev       Date:  2020-02-06

Review 6.  Non-Cancer Effects following Ionizing Irradiation Involving the Eye and Orbit.

Authors:  Juliette Thariat; Arnaud Martel; Alexandre Matet; Olivier Loria; Laurent Kodjikian; Anh-Minh Nguyen; Laurence Rosier; Joël Herault; Sacha Nahon-Estève; Thibaud Mathis
Journal:  Cancers (Basel)       Date:  2022-02-25       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.